Latest Announcements


Press Release




    Events & Presentations

      REMAKING MEDICINE: ON THE RECORD

      EQRx’s mission to significantly lower the cost of new medicines sparks a lot of questions. Our ongoing series explains our disruptive business model that is #RemakingMedicine.

      Mission & Opportunity 1: New Medicines, Radically Lower Prices

      Conquering the next frontier of innovation. Founders explain the EQRx business model on track to increase access to new medicines at unprecedented scale.

      Featuring: Melanie Nallicheri, Alexis Borisy, Dr. Peter Bach

      Mission & Opportunity 2: Dr. Sandra Horning Talks EQRx

      One of the industry's most accomplished drug developers explains the need for expanding access to innovation & why that motivated her to help found EQRx.

      Featuring: Dr. Sandra Horning

      Pipeline Part 1: 10+ Programs & Paths to Approvals

      Our world-renowned clinical leaders dive deep into pipeline data, address key areas of scrutiny, and share our approach to regulatory approvals.

      Featuring: Dr. Vince Miller, Dr. Eric Hedrick, Dr. Christian Antoni

      Pipeline Part 2: Scaling to 20+ Programs by 2022

      The unique Engineering & Development (E&D) approach is rapidly scaling the EQRx pipeline and our cutting-edge partnerships making it possible.

      Featuring: Dr. Carlos Garcia-Echeverria, chief of Rx creation

      Primed for Commercial Success: The Global Buyers’ Club

      EQRx’s unprecedented partnerships with global payers & health systems create a pull-through, rather than push, model for new medicines.

      Featuring: Melanie Nallicheri, Kent Rogers, & EQRx advisor David Joyner, former CVS Health and Caremark EVP

      Investors’ Perspective: Top-Tier Investors Explain EQRx

      Industry-leading investors discuss their unique investment theses and the long-term growth opportunity presented by EQRx’s novel business model.

      Featuring: Eli Casdin, Casdin Capital; Keith Meister, Corvex Management LP, & chariman of CM Life Sciences III; Dr. Krishna Yeshwant, GV

      Q&A for Investors

      This webinar will launch in Q4 of 2021. Submit your questions to investors@EQRx.com for consideration.

      Featuring: Members of EQRx Leadership Team

      We’re Making Progress

      Resources to explore to better understand the progress EQRx has made since our launch two years ago.

      Our Growing Catalog

      • Sugemalimab: Stage IV Data Presented at WCLC 2021, and Stage III Data Presented at ESMO 2021
      •  Aumolertinib: First-line Data Presented at ASCO 2021

      Featured Blogs


      Meet The Team

      Led by world-renowned industry veterans, our passionate team of 200+ changemakers are working relentlessly towards advancing our mission.

      EQRx Executive Team

      Mission Advisory Board

      • Elias A. Zerhouni, M.D.
      • Ellen V. Sigal, Ph.D.
      • Gail R. Wilensky, Ph.D.
      • Mace Rothenberg, M.D.
      • Otis Webb Brawley, M.D.
      • Richard L. Schilsky, M.D., FACP, FSCT, FASCO
      • Sandra J. Horning, M.D.

      Board of Directors

      • Alexis Borisy
      • Clive Meanwell, M.D., Ph.D
      • Eli Casdin
      • Jorge Conde
      • Kathy Giusti
      • Krishna Yeshwant, M.D.
      • Paul L. Berns
      • Sandra Horning, M.D.

      Still have questions?

      Submit them to: investors@eqrx.com


      Get in Touch.

      Stay in The Loop

      Location

      50 Hampshire Street

      Cambridge, MA 02139

      (617) 315-2255